As part of our website, we use cookies to provide you with the highest level of service, including services tailored to your individual needs. By continuing to use the website without changing your cookie settings, you agree to the placement of cookies on your device as described in our Privacy Policy. You can change your cookie settings in your web browser at any time. Acceptance of essential cookies is required for the proper functioning of the website. For more detailed information, please refer to our PRIVACY POLICY.

CALL-POL (Childhood ALL in Poland)

National harmonization of diagnostics and treatment of acute lymphoblastic leukemia in children.
Logo Agencja Badań Medycznych

National harmonization of diagnostics and treatment of acute lymphoblastic leukemia in children.

Childhood ALL in Poland (cALL-POL) project: national harmonization of diagnostics and treatment of acute lymphoblastic leukemia in children – Every year in Poland, over 1,100 children are diagnosed with cancer. Acute lymphoblastic leukemia (ALL) is the most common malignant cancer in children.

CALL-POL is a clinical research project aimed at including all children in Poland newly diagnosed with ALL. The coordinating institution (Medical University of Łódź) will form a consortium with the Medical University of Silesia, Medical University of Lublin, and Łukasiewicz Research Network – EMAG Institute of Innovative Technologies in Katowice, which will jointly conduct nationwide controlled clinical trials involving the treatment of children with leukemia in Poland. For this purpose, all Polish pediatric oncology centers, totaling 16 hospitals, are clinical partners in the project. The CALL-POL consortium will be connected to the iBFM network, which is the world’s largest international clinical research network for leukemia and lymphoma in children. The cost of the study is over 28 million PLN, fully funded by the Medical Research Agency

The main goal of the CALL-POL project is to facilitate access to the latest therapies for Polish children suffering from acute leukemia. The proposed therapies will be available to all children in Poland. Treatment options will be identified using advanced and state-of-the-art molecular diagnostic tools.

The study group will consist of children diagnosed with ALL (acute lymphoblastic leukemia) from all pediatric oncology centers in Poland. Based on incidence rates, approximately 550-600 children are expected to be included in the study, with an average observation period of around 46 months. Diagnostic procedures will be standardized through centralized molecular and genetic analysis of leukemia cells, allowing for treatment methods to be tailored individually for each patient. Additionally, therapy adjustments will be based on the response to treatment, which will be monitored by identifying even single leukemia cells in the bone marrow (measurement of minimal residual disease – MRD). These studies will also rely on unique molecular biology and genetic technologies.

Funding from the Medical Research Agency will allow the use of modern drugs (blinatumomab, bortezomib, ruxolitinib), which are molecularly targeted and tailored individually to each patient. This will likely be the most advanced method of leukemia treatment in the world. The goal of this therapeutic approach is to increase the cure rate for childhood leukemia to around 95%.

In summary, CALL-POL will introduce modern diagnostic methods and molecularly targeted therapies. The experience gained through CALL-POL will improve treatment outcomes for children with acute lymphoblastic leukemia, not only in Poland but also worldwide.

Total project cost: 28,123,231.18 PLN, funding for EMAG: 1,755,169.29 PLN.

This will close in 0 seconds